Favipiravir permanently registered in Russia for COVID-19 treatment

MOSCOW. KAZINFORM - Favipiravir, a drug used to treat COVID-19, has received permanent registration in Russia, Russian Deputy Health Minister Viktor Fisenko said on Thursday, TASS reports.

Related news

Russia documents 23,315 COVID-19 cases over 24 hours

90% of total COVID-19 cases recovered in N Kazakhstan New virus cases at over 1-month low on fewer tests, infection slowdown in S Korea UK records another 54,940 coronavirus cases, 563 deaths

«Following a sped-up procedure, we have greenlit circulation of prevention drugs (vaccines), antiviral therapy drugs - Favipiravir, Remdesivir, and a drug used to mitigate a cytokine storm - Levilimab,» he said, adding that Favipiravir has received a permanent registration certificate.

Earlier, the Russian Federal Service for Surveillance in Healthcare informed that Russia had registered three drugs based on Favipiravir: Avifavir, Areplivir and Coronavir. The watchdog has not received any complaints of non-specific motor disorders during the use of the drugs.